Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LGMN | Q99538 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29822510 | 1.00 | MAPT (0.67) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL4381301 | 0.94 | MAPT (0.59) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL4516029 | 0.88 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL17265648 | 0.87 | ALDH1A1 (0.77) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL520787 | 0.86 | MAPT (0.62) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL17450416 | 0.85 | ALDH1A1 (0.54) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL5236073 | 0.85 | ALDH1A1 (0.60) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL3442442 | 0.83 | ALDH1A1 (0.67) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL7038110 | 0.83 | ALDH1A1 (0.67) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL4163683 | 0.83 | ALDH1A1 (0.58) | MAPTSMN1; SMN2GAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312320-B2 | Method for synthesizing n-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2025-05-27 | — | — | US | claimed |
| CN-118420612-A | Target protein degradation compound based on CDK4/6 inhibitor and preparation method and application thereof | 沈阳药科大学 | 2024-08-02 | — | — | CN | claimed |
| CN-115389661-B | Method for detecting genotoxic impurities in linezolid glucose injection | 华润双鹤药业股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-115047117-B | Detection method for simultaneously determining 3 genetic toxin impurities in linezolid | 北京云鹏鹏程医药科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-113588848-B | Pretreatment solution, pretreatment method and detection method of linezolid glucose solution | 江苏吴中医药集团有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-115925647-A | Production method of linezolid | 湖北广济药业股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115389661-A | Method for detecting genotoxic impurities in linezolid glucose injection | 华润双鹤药业股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2022-08-25 | — | — | US | claimed |
| CN-112457236-B | Preparation method of linezolid intermediate | 泰州申合泰尔生物医药有限公司 | 2022-06-24 | — | — | CN | claimed |
| EP-4001268-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | Hangzhou Dike Technologies Co., Ltd. (CN) | 2022-05-25 | — | — | EP | claimed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | claimed |
| EP-1737850-B1 | A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LTD (IN) | 2007-10-03 | — | — | EP | claimed |
| JP-2007508374-A | — | — | 2007-04-05 | — | — | JP | claimed |
| EP-1680124-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | Pfizer Products Incorporated (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| WO-2005037216-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | MAPT 653/4885SMN1; SMN2 594/4885GAA 382/4885 |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | CYP3A5, CYP1A2, CYP3A4 | MAPT 4807/4885SMN1; SMN2 3644/4885GAA 4009/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | MAPT 661/4885SMN1; SMN2 599/4885GAA 411/4885 |
| US-12312320-B2 | Method for synthesizing n-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | CYP3A5, CYP1A2, CYP3A4 | MAPT 4807/4885SMN1; SMN2 3644/4885GAA 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.